Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
暂无分享,去创建一个
Les Coulton | Karin Vanderkerken | Els Van Valckenborgh | P. Croucher | K. Vanderkerken | E. Van Valckenborgh | H. de Raeve | E. Menu | I. Vande broek | B. Van Camp | Sarah Deleu | Miguel Lemaire | Janine Arts | Eline Menu | Isabelle Vande Broek | Hendrik De Raeve | Ben Van Camp | Peter Croucher | J. Arts | L. Coulton | S. Deleu | M. Lemaire
[1] M. Mapara,et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage , 2007, British journal of haematology.
[2] K. Anderson,et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.
[3] S. Hung,et al. Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. , 2007, Biochemical and biophysical research communications.
[4] D. Ribatti,et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.
[5] S. Schreiber,et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[6] K. Vanderkerken,et al. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. , 2000, The hematology journal : the official journal of the European Haematology Association.
[7] M. Dimopoulos,et al. Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.
[8] P. Croucher,et al. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models , 2009, Leukemia.
[9] O. Sezer,et al. Bortezomib inhibits human osteoclastogenesis , 2007, Leukemia.
[10] P. Elliott,et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.
[11] G. Mundy,et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease , 2007, British journal of haematology.
[12] M. Mohty,et al. VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. , 2007 .
[13] J. Fraczek,et al. Screening of Trichostatin Analogues Based on Cellular Potency in the Murine Multiple Myeloma 5T33MM Model , 2008 .
[14] L. Devy,et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo , 2002, British Journal of Cancer.
[15] N. Munshi,et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.
[16] P. Croucher,et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. , 2005, Methods in molecular medicine.
[17] N. Munshi,et al. New drugs for myeloma. , 2007, The oncologist.
[18] M. Zangari,et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo , 2009, American journal of hematology.
[19] H. Ryoo,et al. Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis , 2007, Experimental & Molecular Medicine.
[20] G. Stein,et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. , 2008, The Journal of clinical investigation.